On January 5, 2026, Executive Vice President Andrew Callos sold 15,000 shares of Cytokinetics, reducing his total holdings to 50,440 shares. This followed two December transactions in which he sold 1,042 shares on December 8 and 52,486 shares on December 5, cumulatively representing roughly $3.46 million in proceeds as reported in SEC filings. Cytokinetics currently has a market capitalization of approximately $7.29 billion and an average daily trading volume of 2,252,943 shares. Over the past twelve months, the stock has traded between a high of $70.98 and a low of $29.31, reflecting increased volatility in the context of ongoing clinical readouts and regulatory milestones for its lead cardiac muscle therapies.

Robert I. Blum, President and CEO of Cytokinetics, is scheduled to present on January 12, 2026 at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Investors will gain insight into the commercial launch progress of MYQORZO™ (aficamten), the company’s FDA- and NMPA-approved treatment for symptomatic obstructive hypertrophic cardiomyopathy, as well as the projected timeline for European Commission approval in Q1 2026. Blum is also expected to update on the clinical development of omecamtiv mecarbil for heart failure with reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction, alongside pre-clinical muscle biology programs. The live webcast will be available via the company’s Investor Relations website, with an archived replay for 90 days post-event.